WuXi AppTec Begins Operations at $100 Million Changzhou Facility

WuXi AppTec reported that Shanghai SynTheAll Pharmaceutical, its small-molecule process development and CMO subsidiary, began operations last month in its new Changzhou facility. The facility, which began construction in 2014, was expected to cost $100 million and offers fully integrated R&D and cGMP services. In 2015, SynTheAll listed on China's Third Board. A few months later, it raised $80 million by selling 6% of STA's shares at a valuation of $1.1 billion for the subsidiary. More details....

Share this with colleagues: